Journal of Reproduction & Infertility

Journal of Reproduction & Infertility

Nesfatin-1, Dopamine, and NADPH levels in Infertile Women with Polycystic Ovary Syndrome: Is There a Relationship Between Their Levels and Metabolic and Hormonal Variables

Authors
Enas Ahmed Hamed 1
Hayam Gaber Sayyed 1
Ahmed Mohamed Abbas 2
Mohamed Maher Abdel Gaber 3
Hassnaa Mahmoud Abd El Aleem 1
1 Department of Medical Physiology, Faculty of Medicine, Assiut University, Assiut, Egypt
2 Department of Obstetrics and Gynecology, Faculty of Medicine, Assiut University, Assiut, Egypt
3 Department of Clinical Pathology, Faculty of Medicine, Assiut University, Assiut, Egypt
10.18502/jri.v23i3.10006
Abstract
Background: Polycystic ovary syndrome (PCOS) is commonest endocrine disease occurring in women of reproductive age. This study conducted to clarify altered concentrations of Nesfatin-1, nicotinamide adenine dinucleotide phosphate (NADPH), and dopamine in PCOS women and controls. Also, to assess their role in PCOS pathophysiology and their correlation with measured biochemical parameters. Methods: In this observational study, 60 PCOS patients and 24 controls included. Medical history was recorded and full examinations were done. Serum concentrations of lipid profile, fasting blood glucose (FBG), fasting insulin (FSI), luteinizing hormone (LH), follicle stimulating hormone (FSH), prolactin, testosterone, progesterone, estradiol, Nesfatin-1, dopamine, and NADPH were measured by ELISA kits. Values were analyzed using unpaired t-test and Pearson Chi-square test. The p<0.05 was considered statistically significant. Results: In this study, there was significantly elevated waist hip ratio (WHR) and body mass index (BMI) in PCOS patients versus controls (p<0.0001 and p=0.014). There was significant increase in FSH, LH, prolactin, estradiol, testosterone, Nesfatin-1, and dopamine (p=0.021, p=0.015, p<0.0001, p<0.0001, p=0.006, p=0.017, p<0.0001) and decrease of NADPH (p<0.0001) in PCOS patients. There were significant positive correlations between Nesfatin-1, prolactin, and dopamine levels. Also, there was significant positive correlation between dopamine and BMI, FSI, FSH, LH, estradiol, and prolactin levels; however, significant negative correlations observed between NADPH and BMI, FSI, estradiol, and prolactin levels. Conclusion: Elevated serum Nesfatin-1 concentrations and their association with hyperprolactinemia indicate that they have a role in PCOS pathophysiology. Moreover, elevated dopamine and decreased NADPH concentrations could play role in PCOS pathogenesis.
Keywords
Dopamine
Infertility
Nesfatin
1
Nicotinamide adenine dinucleotide phosphate
polycystic ovarian syndrome
prolactin
  1. Regidor PA, Mueller A, Sailer M, Gonzalez Santos F, Rizo JM, Egea FM. Chronic inflammation in PCOS: the potential benefits of specialized proresolving lipid mediators (SPMs) in the improvement of the resolutive response. Int J Mol Sci. 2021;22(1):384.
  2. Daghestani MH. Rs1799817 in INSR associates with susceptibility to polycystic ovary syndrome. J Med Biochem. 2020;39(2):149-59.
  3. Prinz P, Goebel-Stengel M, Teuffel P, Rose M, Klapp BF, Stengel A. Peripheral and central localization of the nesfatin-1 receptor using autoradiography in rats. Biochem Biophysic Res Commun. 2016;470(3):521-7.
  4. Gao X, Zhang K, Song M, Li X, Luo L, Tian Y, et al. Role of nesfatin-1 in the reproductive axis of male rat. Sci Rep. 2016;6:32877.
  5. Kim J, Yang H. Nesfatin-1 as a new potent regulator in reproductive system. Dev Reprod. 2012;16(4):253-64.
  6. Dore R, Levata L, Lehnert H, Schulz C. Nesfatin-1: functions and physiology of a novel regulatory peptide. J Endocrinol. 2017;232(1):R45-R65.
  7. Nakata M, Manaka K, Yamamoto S, Mori M, Yada T. Nesfatin-1 enhances glucose-induced insulin secretion by promoting Ca2+ influx through L-type channels in mouse islet β-cells. Endocrine J. 2011; 58(4):305-13.
  8. Alp E, Görmüş U, Güdücü N, Bozkurt S. Nesfatin-1 levels and metabolic markers in polycystic ovary syndrome. Gynecol Endocrinol. 2015;31(7):543-7.
  9. Deniz R, Gurates B, Aydin S, Celik H, Sahin I, Baykus Y, et al. Nesfatin-1 and other hormone alterations in polycystic ovary syndrome. Endocrine. 2012;42(3):694-9.
  10. Ademoglu EN, Gorar S, Carlıoglu A, Dellal FD, Berberoglu Z, Akdeniz D, et al. Plasma nesfatin-1 levels are increased in patients with polycystic ovary syndrome. J Endocrinol Invest. 2014;37(8):715-9.
  11. Nuñez-Calonge R, Cortés S, Gonzalez LMG, Kireev R, Vara E, Ortega L, et al. Oxidative stress in follicular fluid of young women with low response compared with fertile oocyte donors. Reprod Biomed Online. 2016;32(4):446-56.
  12. Su P, Bretz JD, Gunaratne GS, Marchant JS, Walseth TF, Slama JT. Chemo-enzymatic synthesis of adenine substituted nicotinic acid adenine dinucleotide phosphate (NAADP) analogs. Bioorg Med Chem. 2021;30:115901.
  13. Kim SH, Kim H, Lee JH, Park JW. Oxalomalate suppresses metastatic melanoma through IDH-targeted stress response to ROS. Free Radic Res. 2019;53(4):418-29.
  14. Parillo F, Maranesi M, Mignini F, Marinelli L, Di Stefano A, Boiti C, et al. Evidence for a dopamine intrinsic direct role in the regulation of the ovary reproductive function: In vitro study on rabbit corpora lutea. PLoS One. 2014;9(8):e104797.
  15. Beaulieu JM, Borrelli E, Carlsson A, Caron MG, Civelli O, Espinoza S, et al. Dopamine receptors (version 2019.4) in the IUPHAR/BPS guide to pharmacology database. IUPHAR/BPS guide to pharmacology CITE. 2019;2019(4):1-28.
  16. Lai Q, Xiang W, Li Q, Zhang H, Li Y, Zhu G, et al. Oxidative stress in granulosa cells contributes to poor oocyte quality and IVF-ET outcomes in women with polycystic ovary syndrome. Front Med. 2018;12(5):518-24.
  17. Sahin FK, Sahin SB, Ural UM, Cure MC, Senturk S, Tekin YB, et al. Nesfatin-1 and vitamin D levels may be associated with systolic and diastolic blood pressure values and hearth rate in polycystic ovary syndrome. Bosn J Basic Med Sci. 2015;15(3):57-63.
  18. Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2:16057.
  19. Masjedi F, Keshtgar S, Agah F, Karbalaei N. Association between sex steroids and oxidative status with vitamin D levels in follicular fluid of non-obese PCOS and healthy women. J Reprod Infertil. 2019;20(3):132-42.
  20. Singh Y, Garg M, Tandon N, Marwaha RK. A study of insulin resistance by HOMA-IR and its cut-off value to identify metabolic syndrome in urban Indian adolescents. J Clin Res Pediatr Endocrinol. 2013;5(4):245-51.
  21. Keen MA, Shah IH, Sheikh G. Cutaneous manifestations of polycystic ovary syndrome: A crosssectional clinical study. Indian Dermatol Online J. 2017;8(2):104-10.
  22. Abdelazim IA, Alanwar A, AbuFaza M, Amer OO, Bekmukhambetov Y, Zhurabekova G, et al. Elevated and diagnostic androgens of polycystic ovary syndrome. Prz Menopauzalny. 2020;19(1):1-5.
  23. Lazúrová I, Lazúrová Z, Figurová J, Ujházi S, Dravecká I, Mašlanková J, et al. Relationship between steroid hormones and metabolic profile in women with polycystic ovary syndrome. Physiol Res. 2019;68(3):457-65.
  24. Kirmizi DA, Baser E, Onat T, Caltekin MD, Yalvac ES, Kara M, et al. Sexual function and depression in polycystic ovary syndrome: Is it associated with inflammation and neuromodulators? Neuropeptides. 2020;84:102099.
  25. Tao X, Chen L, Cai L, Ge S, Deng X. Regulatory effects of the AMPKα-SIRT1 molecular pathway on insulin resistance in PCOS mice: an in vitro and in vivo study. Biochem Biophys Res Commun. 2017;494(3-4):615-20.
  26. Kucur C, Kucur SK, Gozukara I, Seven A, Yuksel KB, Keskin N, et al. Extended high frequency audiometry in polycystic ovary syndrome. Sci World J. 2013;2013:482689.
  27. Cameron JL, Jain R, Rais M, White AE, Beer TM, Kievit P, et al. Perpetuating effects of androgen deficiency on insulin resistance. Int J Obes (Lond). 2016;40(12):1856-63.
  28. Ng NYH, Jiang G, Cheung LP, Zhang Y, Tam CHT, Luk AOY, et al. Progression of glucose intolerance and cardiometabolic risk factors over a decade in Chinese women with polycystic ovary syndrome: a case-control study. PLoS Med. 2019; 16(10):e1002953.
  29. Spinedi E, Cardinali DP. The polycystic ovary syndrome and the metabolic syndrome: a possible chronobiotic-cytoprotective adjuvant therapy. Int J Endocrinol. 2018;2018:1349868.
  30. Lath R, Shendye R, Jibhkate A. Insulin resistance and lipid profile in polycystic ovary syndrome. Asian J Biomed Pharm Sci. 2015;5(47):30.
  31. Kiranmayee D, Kavya K, Himabindu Y, Sriharibabu M, Madhuri GLJ, Venu S. Correlations between anthropometry and lipid profile in women with PCOS. J Hum Reprod Sci. 2017;10(3):167-72.
  32. Javaid S, Ahmed U, Lone KP, Ikram N. Plasma dopamine levels in Polycystic Ovary Syndrome women. Pakistan J Physiol. 2019;15(3):49-52.
  33. Malini NA, George KR. Evaluation of different ranges of LH: FSH ratios in polycystic ovarian syndrome (PCOS)–Clinical based case control study. Gen Comp Endocrinol. 2018;260:51-7.
  34. Moffett RC, Naughton V. Emerging role of GIP and related gut hormones in fertility and PCOS. Peptides. 2020;125:170233.
  35. Nath CK, Barman B, Das A, Rajkhowa P, Baruah P, Baruah M, et al. Prolactin and thyroid stimulating hormone affecting the pattern of LH/FSH secretion in patients with polycystic ovary syndrome: a hospital-based study from north east India. J Fam Med Prim Care. 2019;8(1):256-60.
  36. Bouckenooghe T, Sisino G, Aurientis S, Chinetti-Gbaguidi G, Kerr-Conte J, Staels B, et al. Adipose tissue macrophages (ATM) of obese patients are releasing increased levels of prolactin during an inflammatory challenge: a role for prolactin in diabesity? Biochim Biophys Acta. 2014;1842(4):584-93.
  37. Andersen M, Glintborg D. Metabolic syndrome in hyperprolactinemia. Front Horm Res. 2018;49:29-47.
  38. Auriemma RS, De Alcubierre D, Pirchio R, Pivonello R, Colao A. Glucose abnormalities associated to prolactin secreting pituitary adenomas. Front Endocrinol (Lausanne). 2019;10:327.
  39. Ayada C, Toru Ü, Korkut Y. Nesfatin-1 and its effects on different systems. Hippokratia. 2015;19 (1):4-10.
  40. Könczöl K, Bodnár I, Zelena D, Pintér O, Papp RS, Palkovits M, et al. Nesfatin-1/NUCB2 may participate in the activation of the hypothalamic–pituitary–adrenal axis in rats. Neurochem Int. 2010;57(3):189-97.
  41. Könczöl K, Pintér O, Ferenczi S, Varga J, Kovács K, Palkovits M, et al. Nesfatin-1 exerts longterm effect on food intake and body temperature. Int J Obes (Lond). 2012;36(12):1514-21.
  42. Saller S, Kunz L, Berg D, Berg U, Lara H, Urra J, et al. Dopamine in human follicular fluid is associated with cellular uptake and metabolism-dependent generation of reactive oxygen species in granulosa cells: implications for physiology and pathology. Hum Reprod. 2014;29(3):555-67.
  43. Musalı N, Özmen B, Şükür YE, Ergüder Bİ, Atabekoğlu CS, Sönmezer M, et al. Follicular fluid norepinephrine and dopamine concentrations are higher in polycystic ovary syndrome. Gynecol Endocrinol. 2016;32(6):460-3.
  44. Ferrero H, Díaz-Gimeno P, Sebastián-León P, Faus A, Gómez R, Pellicer A. Dysregulated genes and their functional pathways in luteinized granulosa cells from PCOS patients after cabergoline treatment. Reproduction. 2018;155(4):373-81.
  45. Chaudhari N, Dawalbhakta M, Nampoothiri L. GnRH dysregulation in polycystic ovarian syndrome (PCOS) is a manifestation of an altered neurotransmitter profile. Reprod Biol Endocrinol. 2018;16(1):37.
  46. González F. Inflammation in polycystic ovary syndrome: underpinning of insulin resistance and ovarian dysfunction. Steroids. 2012;77(4):300-5.
  47. Zuo T, Zhu M, Xu W. Roles of oxidative stress in polycystic ovary syndrome and cancers. Oxid Med Cell Longev. 2016;2016:8589318.
Journal of Reproduction & Infertility
Volume 23, Issue 3
Summer 2022
Pages 160-168